Polyneuron

Polyneuron

Polyneuron

Swiss biotech start-up. We’re using our Antibody-Catch® technology to develop the most accurate treatment of rare autoimmune disorders.
Type
B2b
Founded
2014
Raised
$41M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$15,281,700
Venture capital (Series A) - 2020
Sofinnova Partners New Enterprise Associates HBM Healthcare Investments AG
$22,600,000
Venture capital (Series A) - 2019
Sofinnova Partners New Enterprise Associates
Team Size
1–10
Employees
$15,281,700 Venture capital (Series A)
FinSMEs

Polyneuron Raises Additional CHF 14M; Expands Series A to CHF 36.5M

$22,600,000 Venture capital (Series A)
PE HUB

Swiss biotech company Polyneuron inks funding

$3,109,641 Seed fund
FinSMEs

Polyneuron Pharmaceuticals Completes CHF3.1M in Seed Financing

Health
Seed fund
startupticker

Polyneuron Pharmaceuticals closes CHF 3 Million seed financing round.ch | The Swiss Startup News channel

Health Funding